局限性前列腺癌患者的决策后悔:系统评价与Meta分析
该系统评价与Meta分析纳入14项研究共17883例局限性前列腺癌患者,汇总显著决策后悔发生率为20%(95%CI 16-23)。主动监测者后悔率较低(13%),放疗(19%)与前列腺切除术(18%)间差异不大。治疗后肠道、性及泌尿功能较差、决策参与度低及黑人种族与更高后悔相关,但证据存在矛盾且确定性低或中等。
要点
- 局限性前列腺癌患者显著决策后悔的汇总发生率为20%(95%CI 16-23)。
- 主动监测者后悔率为13%,放疗者为19%,前列腺切除术者为18%。
- 治疗后肠道、性及泌尿功能较差、决策参与度低及黑人种族与更高后悔相关。
核心结论
- 相当比例男性在局限性前列腺癌诊断后经历决策后悔。
- 监测功能症状增加者并通过教育和决策辅助提高患者决策参与度可能减少后悔。
研究设计与样本
- 系统检索MEDLINE、Embase和PsychINFO数据库,纳入评估局限性前列腺癌患者决策后悔发生率或患者、治疗、肿瘤预后因素的研究。
- 对显著后悔的汇总发生率进行计算,并按识别的每个因素进行正式预后因素评价。
主要发现
- 14项研究共17883例患者中,显著决策后悔的汇总发生率为20%(95%CI 16-23)。
- 主动监测者后悔率为13%,放疗者为19%,前列腺切除术者为18%。
- 治疗后肠道、性及泌尿功能较差者、决策参与度较低者及黑人种族者后悔更高。
- 证据存在矛盾, findings的确定性为低或中等。
关键数值与推荐
- 显著决策后悔的汇总发生率为20%(95%CI 16-23),基于14项研究17883例患者。
- 主动监测者后悔率为13%,放疗者为19%,前列腺切除术者为18%。
临床怎么用
- 作者认为,监测功能症状增加者并通过教育和决策辅助提高患者决策参与度可能减少后悔。
局限性
- 证据存在矛盾, findings的确定性为低或中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Treatment choice for localised prostate cancer remains a significant challenge for patients and clinicians, with uncertainty over decisions potentially leading to conflict and regret. There is a need to further understand the prevalence and prognostic factors of decision regret to improve patient quality of life. OBJECTIVE: To generate the best estimates for the prevalence of significant decision regret localised prostate cancer patients, and to investigate prognostic patient, oncological, and treatment factors associated with regret. EVIDENCE ACQUISITION: We performed a systematic search of MEDLINE, Embase, and PsychINFO databases including studies evaluating the prevalence or patient, treatment, or oncological prognostic factors in localised prostate cancer patients. A pooled prevalence of significant regret was calculated with the formal prognostic factor evaluation conducted per factor identified. EVIDENCE SYNTHESIS: Significant decision regret was present in a pooled 20% (95% confidence interval 16-23) of patients across 14 studies and 17883 patients. This was lower in active surveillance (13%), with little difference between those who underwent radiotherapy (19%) and those who underwent prostatectomy (18%). Evaluation of individual prognostic factors demonstrated higher regret in those with poorer post-treatment bowel, sexual, and urinary function; decreased involvement in the decision-making process; and Black ethnicity. However, evidence remains conflicting, with low or moderate certainty of findings. CONCLUSIONS: A significant proportion of men experience decision regret after a localised prostate cancer diagnosis. Monitoring those with increased functional symptoms and improving patient involvement in the decision-making process through education and decision aids may reduce regret. PATIENT SUMMARY: We looked at how common regret in treatment decisions is after treatment for early-stage prostate cancer and factors linked with this. We found that one in five regret their decision, with those who had experienced side effects or were less involved in the decision-making process more likely to have regret. By addressing these, clinicians could reduce regret and improve quality of life.
引用
- Fanshawe JB, Wai-Shun Chan V, Asif A, et al. Decision Regret in Patients with Localised Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2023. PMID: 36870852. doi:10.1016/j.euo.2023.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。